Thumbnail
Access Restriction
Open

Author Liu, Hao ♦ Rose, Marie E. ♦ Culver, Sherman ♦ Ma, Xiecheng ♦ Dixon, C. Edward ♦ Graham, Steven H.
Source United States Department of Energy Office of Scientific and Technical Information
Content type Text
Language English
Subject Keyword APPLIED LIFE SCIENCES ♦ BRAIN ♦ INFLAMMATION ♦ INJURIES ♦ LYMPHOKINES ♦ MACROPHAGES ♦ NERVE CELLS ♦ RATS ♦ RECEPTORS ♦ SPINAL CORD ♦ TRANSCRIPTION
Abstract Rosiglitazone, a potent peroxisome proliferator-activated receptor (PPAR)-γ agonist, has been shown to confer neuroprotective effects in stroke and spinal cord injury, but its role in the traumatic brain injury (TBI) is still controversial. Using a controlled cortical impact model in rats, the current study was designed to determine the effects of rosiglitazone treatment (6 mg/kg at 5 min, 6 h and 24 h post injury) upon inflammation and histological outcome at 21 d after TBI. In addition, the effects of rosiglitazone upon inflammatory cytokine transcription, vestibulomotor behavior and spatial memory function were determined at earlier time points (24 h, 1–5 d, 14–20 d post injury, respectively). Compared with the vehicle-treated group, rosiglitazone treatment suppressed production of TNFα at 24 h after TBI, attenuated activation of microglia/macrophages and increased survival of CA3 neurons but had no effect on lesion volume at 21 d after TBI. Rosiglitazone-treated animals had improved performance on beam balance testing, but there was no difference in spatial memory function as determined by Morris water maze. In summary, this study indicates that rosiglitazone treatment in the first 24 h after TBI has limited anti-inflammatory and neuroprotective effects in rat traumatic injury. Further study using an alternative dosage paradigm and more sensitive behavioral testing may be warranted. - Highlights: • Effects of rosiglitazone after CCI were evaluated using a rat TBI model. • Rosiglitazone suppressed production of TNFα at 24 h after CCI. • Rosiglitazone inhibited microglial activation at 21 d after CCI. • Rosiglitazone increased survival of CA3 neurons at 21 d after CCI. • Rosiglitazone-treated animals had improved performance in beam balance testing.
ISSN 0006291X
Educational Use Research
Learning Resource Type Article
Publisher Date 2016-04-15
Publisher Place United States
Journal Biochemical and Biophysical Research Communications
Volume Number 472
Issue Number 4


Open content in new tab

   Open content in new tab